Uterine Fibroids

Uterine Fibroids

Last updated: 05/2021

1 Overview

Summary and Quick Facts

  • Uterine fibroids are abnormal growths of the uterus that can cause symptoms like pelvic pain and prolonged menstrual bleeding. Importantly, fibroids are not cancer, and they typically do not become cancerous. In fact, most women will have some uterine fibroids at some point in their lives and experience little to no symptoms.
  • This protocol covers causes of and conventional treatments of uterine fibroids, as well as dietary and lifestyle considerations associated with lower fibroid risk and what emerging medical approaches appear promising. Several dietary supplements that may compliment conventional treatments are covered, as well.
  • Strategies in this protocol, in conjunction with appropriate medically supervised treatment, can provide a comprehensive approach to ensure uterine health.
  • Green tea has been shown in clinical trials to help ease symptoms associated with fibroids, and low vitamin D levels have been linked to fibroids in several observational studies.

Uterine fibroids are noncancerous growths of the smooth muscle within the uterine wall. They are the most common benign pelvic tumor in women. Up to 75% of women will have uterine fibroids at some point during their lives, with the majority causing no symptoms and occurring during the reproductive years. Fortunately, natural integrative interventions such as green tea may help ease symptoms associated with fibroids.

Risk Factors for Uterine Fibroids

  • Higher estrogen and progesterone levels
  • Higher body weight and body mass index (BMI)
  • Ethnicity (African-American women have a 3-fold greater risk as compared to Caucasian women)
  • Women with a first-degree relative with uterine fibroids have a 2.5-fold increased chance of developing fibroids themselves

Symptoms Associated with Uterine Fibroids

Uterine fibroids often do not cause noticeable signs or symptoms, but may present with the following:

  • Heavy, prolonged menstrual bleeding
  • Pelvic pain or fullness
  • Increased urinary frequency or incontinence

Conventional Medical Treatments

For fibroids that require intervention, treatment can be approached medically or surgically.

  • Drugs (gonadotropin-releasing hormone agonists, anti-progestogen therapy, tranexamic acid, non-steroidal anti-inflammatory drugs [NSAIDs])
  • Minimally-invasive procedures (uterine artery embolization, endometrial ablation, and magnetic resonance-guided focused ultrasound surgery)
  • Surgical procedures (hysterectomy and myomectomy)

Note: A surgical procedure known as uterine power morcellation involves shredding uterine tissue into smaller pieces so that it may be removed through laparoscopic surgery. Life Extension reported on the dangers of this procedure in its July 2014 issue and on the FDA’s lack of oversight and insufficient protection of women from this procedure.

Natural Therapies for Uterine Fibroids

Lifestyle and Dietary Changes:

  • Consume greater quantities of vegetables, fruits, and dairy products with an emphasis on lower glycemic index foods
  • Exercise at least seven hours per week

Integrative Interventions:

  • Green Tea and EGCG: Epigallocatechin gallate (EGCG), a polyphenol found in green tea, was found to significantly reduce fibroid volume and symptoms.
  • Vitamin D: Women with lower serum levels of vitamin D are more likely to develop uterine fibroids.
  • Curcumin: Curcumin has been shown to inhibit fibroid cell growth.
  • Cimicifuga racemosa (Black Cohosh) Extract: Black cohosh has been found to help decrease fibroid size in women with menopausal symptoms and fibroids.

2 Introduction

Uterine fibroids, also called uterine leiomyomas, are noncancerous growths of the uterus. They are the most common benign pelvic tumor in women (Eltoukhi 2014; Bulun 2013; Mitwally 2013; Mayo Clinic 2014a; Stine 2014; Hodge 2007). Although very controversial, with some sources stating definitively that uterine fibroids do not transform into cancer, other data suggest a very rare risk for transformation (Clement 1993).

In a US study with women age 35 to 49 years, the incidence of uterine fibroids by age 35 was 60% among African-American women, increasing to greater than 80% by age 50, whereas Caucasian women showed an incidence of 40% by age 35 and almost 70% by age 50 (Day Baird 2003). Up to 75% of women will have uterine fibroids at some point during their lives, though they often do not cause symptoms (Ferri 2014; Mayo Clinic 2014a).

Symptoms associated with uterine fibroids include heavy, prolonged menstrual bleeding; pelvic pain, pressure, or fullness; frequent urination or incontinence; constipation; infertility; and back or leg pain (Mayo Clinic 2014a; Khan 2014).

Uterine Fibroid  

Fibroids can vary in size, number, and location. There are multiple types of uterine fibroids, each characterized based on their location (Mayo Clinic 2014a):

  • intramural fibroids grow within the muscular wall of the uterus
  • submucosal fibroids grow toward and into the uterine cavity from the uterine wall
  • subserosal fibroids grow toward the outside of the uterus
  • cervical fibroids are located in the cervix of the uterus (Mitwally 2013)

Treatment of uterine fibroids is often dependent on a woman’s symptoms and desire to maintain fertility. Conventional treatment options include gonadotropin-releasing hormone agonists, which temporarily stop the menstrual cycle and help decrease fibroid size; estrogen/progestin hormone therapy when control of excessive bleeding is a primary concern; minimally invasive surgical treatment such as myomectomy to remove fibroids; uterine artery embolization to disrupt blood supply to the fibroid; and surgical procedures such as hysterectomy (removal of the uterus) (Evans 2007). Uterine fibroids are a common indication for hysterectomy, and approximately one-third of hysterectomies in the United States are performed because of symptomatic fibroids (Elsevier BV 2011).  

Uterine power morcellation, which can be performed as part of a laparoscopic hysterectomy, is a procedure in which a woman’s uterus is shredded into small pieces using an electrically powered device and then removed through a small incision in her abdomen. Although this approach is less surgically invasive than the traditional abdominal hysterectomy, little-appreciated until recently is the risk for distribution of occult, cancerous uterine tissue throughout the abdominal cavity as a direct result of the procedure. During the surgical shredding process, small pieces of uterine tissue can be dispersed into the abdominal cavity. While this does not cause problems in most cases, one in 350 women with fibroids has a fibroid tumor that harbors undetected malignant tissue (ie, leiomyosarcoma) at the time of the operation. The surgical shredding can spread leiomyosarcoma cells in the abdominal cavity, which can result in the dissemination of this aggressive form of cancer (Park 2011). In light of these revelations, in mid-2014 the US Food and Drug Administration (FDA) warned against the use of uterine power morcellation procedures (FDA 2014a), and some insurers stopped covering the cost of these operations (Reuters 2014b). The July 2014 issue of Life Extension magazine contains a detailed exposé of the dangers of these potentially deadly procedures along with an account of the diligent work of Dr. Hooman Noorchashm of Harvard Medical School and Brigham and Women’s Hospital and his wife, Dr. Amy Reed, who developed a rare form of uterine cancer after undergoing uterine power morcellation. Drs. Noorchashm and Reed relentlessly campaigned to bring the shortcomings of power morcellation to light, and as a result some medical centers have modified their positions on uterine power morcellation.

In this protocol you will learn about causes of uterine fibroids, how they develop, and how they are conventionally treated. You will discover several novel and emerging treatment approaches that may improve outcomes for women with fibroids. Also, we will review a number of dietary and lifestyle considerations that may help prevent uterine fibroids. Additionally, we will explore integrative and natural approaches to fibroids, such as the ability of green tea extract to significantly reduce the size of fibroids as well as the severity of fibroid symptoms.

3 Background

Uterine fibroids are derived from smooth muscle within the uterine wall (Mitwally 2013). Fibroids may also be located in the cervix; the broad ligament, which connects the uterus to the pelvic wall; or can be attached to the interior or exterior of the uterus by a stalk, in which case they are called pedunculated leiomyomas. In some cases, fibroids may develop in other abdominal structures; these are called parasitic leiomyomas (Ferri 2014; Phupong 2003; Jebunnaher 2013). Women can have a single fibroid or multiple fibroids of different sizes and in different locations (Elsevier BV 2011).

The exact cause of uterine fibroids is not completely understood. However, the sex hormones estrogen and progesterone play an important role in fibroid growth (Mitwally 2013). Estrogen and progesterone control the growth of the uterine lining (endometrium) during a woman’s reproductive cycle and help prepare the uterus for pregnancy (Goldsmith 2009). The incidence of fibroids fluctuates throughout different hormonal phases of a woman’s life, with the majority occurring during reproductive years (Ciavattini 2013). Some, but not all, studies have found that high estrogen levels and increased blood flow during pregnancy can cause existing fibroids to enlarge (Ferri 2014; UMMC 2014). This effect may depend on the trimester of pregnancy and size of the fibroids, though one study found no change in fibroid size for most women during pregnancy. In that study, the fibroids that did enlarge grew less than 25% (Lev-Toaff 1987; Aharoni 1988). After menopause, when hormone levels decline, existing fibroids often decrease in size (Elsevier BV 2011).

Compared with surrounding normal tissue, fibroids contain higher levels of receptors for progesterone and estrogen and are more responsive to hormonal stimulation. Estradiol, a type of estrogen, promotes fibroid cell replication, while progesterone blocks fibroid cell death. These combined effects can result in growth of fibroid tissue (Elsevier BV 2011). Moreover, fibroid tissue has higher levels of the enzyme aromatase, which converts testosterone into estrogen, compared with healthy uterine tissue. This may lead to higher levels of estrogen in the fibroid tissue, which may further stimulate fibroid growth (Ishikawa 2006; Bulun 2013; Ishikawa 2009).

4 Risk Factors

Body Weight

Women who weigh more than 154 pounds have three times the risk of developing fibroids than women weighing less than 110 pounds (Elsevier BV 2011). In one study, women with fibroids were significantly more likely to have a higher body mass index compared to women without uterine fibroids (He 2013). Fat tissue converts testosterone into estrogen, and obesity can lead to decreased levels of a protein called sex hormone binding globulin that binds to estrogen and progesterone, resulting in more unbound (active) hormones. These combined effects result in more estrogen and progesterone within the uterus, which may lead to fibroid development (Wise 2005; Sam 2007; Ciavattini 2013).


African-American women have an approximately 3-fold greater risk of developing fibroids than Caucasian women (Elsevier BV 2011). Although the precise reasons for this are unclear, increased levels of the aromatase enzyme in fibroid tissue itself may contribute; fibroid tissue from African-American women has been shown to contain higher aromatase levels than fibroid tissue from Caucasian and Japanese women (Ciavattini 2013; Bulun 2013; Ishikawa 2009).

Family History and Genetics

There is considerable evidence that heredity may be involved in some cases of uterine fibroids (Ligon 2001). Women who have a first-degree relative with uterine fibroids have a 2.5-fold increased chance of developing fibroids (Elsevier BV 2011). Also, identical twins are more likely to have fibroids than non-identical twins (Mayo Clinic 2014a).

Dietary Habits and Alcohol

There is some evidence suggesting a correlation between uterine fibroid development and dietary habits. Women who eat more red meat, drink more alcohol, and eat fewer vegetables and fruits have a significantly higher chance of developing fibroids (Mayo Clinic 2014a; Chiaffarino 1999; He 2013; Nagata 2001). Among African-American women, long-term alcohol consumption has been associated with an increased risk of fibroids (Wise 2004).

High Blood Pressure

A study of over 104 000 women reported that for every 10 mm Hg increase in diastolic blood pressure, the risk of fibroid development increased an average of 8-10%. It is hypothesized that this increase may be caused by the release of cytokines in the smooth muscle of the uterus (Boynton-Jarrett 2005; Elsevier BV 2011).

Other Risk Factors

Other factors associated with an increased risk of fibroid growth include first menstruation before 10 years of age, not having children, polycystic ovary syndrome, diabetes, and being over 40 years of age (Ciavattini 2013; Elsevier BV 2011; Islam 2013). Fibroids are associated with a group of conditions – diabetes, obesity, hypertension, and polycystic ovary syndrome – that are also associated with metabolic syndrome. Metabolic syndrome and the aforementioned conditions are often associated with insulin resistance and abnormal glucose metabolism. This connection is also suggested by evidence presented elsewhere in this protocol, as fibroids appear to respond to the antidiabetic, insulin-sensitizing drug metformin; are associated with excessive carbohydrate consumption; and respond to exercise. Many, but not all, researchers investigating this association have confirmed a relationship between abnormal glucose metabolism and uterine fibroids (Wise 2007; Kong 2014; Takeda 2008; Sadlonova 2008; Ekpo 2013).

5 Signs and Symptoms

Uterine fibroids oftentimes do not cause noticeable signs or symptoms (Mitwally 2013). However, fibroids can cause pain, pressure, and a significant reduction in quality of life (Bulun 2013; Zimmermann 2012). Symptoms are generally dependent on the number, location, and size of fibroids (Mayo Clinic 2014a). On rare occasions, extremely large fibroids have been known to cause the uterus to expand to a size similar to that of the sixth or seventh month of pregnancy (Bulun 2013).

The most frequently reported symptom of uterine fibroids is increased and prolonged menstruation, that is, heavy bleeding and bleeding outside of the normal menstrual cycle (Gonsalves 2008; Mayo Clinic 2014a; Ferri 2014; Zimmermann 2012). Other possible fibroid symptoms include pelvic pain or pressure, leg or back pain, painful intercourse, increased urinary frequency or incontinence, and constipation. Infertility or pregnancy complications, including miscarriage, are also possible (Zimmermann 2012; Gonsalves 2008; Mitwally 2013).

Symptoms can also vary according to the location of the fibroid. Submucosal fibroids grow toward and into the inner uterine cavity from the uterine wall and often cause heavy menstrual bleeding or fertility problems. Subserosal fibroids grow toward the outside of the uterus and may cause urinary problems, rectal pressure, or backache as a result of pressure on related structures. Intramural fibroids grow within the muscular wall of the uterus, potentially leading to heavy, prolonged periods; pain; and pressure (Mayo Clinic 2014a). 

Less common complications of uterine fibroids include fluid accumulation in the abdominal cavity (ascites), slow blood flow in the veins of the legs, or rarely, transformation to a cancerous uterine sarcoma (Ferri 2014; Khan 2014; ACS 2014a).

6 Diagnosis

A physician may suspect the presence of uterine fibroids if a patient has sensations of pelvic fullness, increased or extended menstrual bleeding, or is experiencing infertility. Sometimes fibroids are diagnosed during routine pelvic examinations (Elsevier BV 2011). In order to confirm the presence of uterine fibroids, physicians generally use one or more diagnostic procedures.


Ultrasonography (ultrasound) is the most frequently used diagnostic tool for fibroids because of its availability and relative low cost. However, the accuracy and diagnostic capability of ultrasonography is highly dependent on the technician performing the scan, and the images that ultrasonography provides are not as consistently reproducible as those of magnetic resonance imaging (MRI). Ultrasonography can be performed transabdominally or transvaginally; accuracy is improved when both are performed. Transvaginal ultrasound is able to detect smaller fibroids than transabdominal scans. A skilled technician can detect fibroids as small as 5 mm with transvaginal ultrasonography (Khan 2014).

Magnetic Resonance Imaging

MRI is often used as a second diagnostic option if the physician is uncertain about the type of pelvic mass a patient has. MRI is a more costly procedure than ultrasonography; however, it is more sensitive, with the ability to detect fibroids in 88-93% of patients. Also, the scan is better able to distinguish between submucosal, intramural, and subserosal fibroids, which is important for making future treatment decisions (Khan 2014; Mitwally 2013). 

Saline Infusion Sonohysterography

Saline infusion sonohysterography is occasionally used for diagnostic purposes to supplement either ultrasonography or MRI. In this procedure, sterile saline is injected into the uterus to expand it, allowing clearer images of uterine growths, which are obtained by ultrasonography (ACOG 2004). The quality of the images is dependent on the amount of uterine expansion and therefore, the amount of associated discomfort the patient can tolerate (Khan 2014). This test may be used if a woman has excessive menstrual bleeding or if ultrasonography tests are normal (Mayo Clinic 2014a).


Hysteroscopy is performed by inserting a small, lighted instrument called a laparoscope into the uterus for direct visualization. The physician then injects saline or carbon dioxide gas into the uterus to allow expansion and examination through the laparoscope (Mayo Clinic 2014a). Hysteroscopy can be diagnostic and/or surgical, as a biopsy can be performed, and some fibroids can be surgically removed during the procedure (Ferri 2014; UMMC 2014; ASRM 2012a; A.D.A.M. 2012; ACOG 2011). 

Additional Tests

Excessive bleeding caused by fibroids may result in iron-deficiency anemia (Elsevier BV 2011). Symptoms of iron-deficiency anemia include fatigue, pale skin, weakness, shortness of breath, chest pain, headache, and dizziness (Mayo Clinic 2014b). A physician may request a complete blood count (CBC) to analyze the number of red blood cells (Elsevier BV 2011). 

If uterine fibroids are causing significant urinary symptoms, doctors may also perform tests to examine a patient’s urinary system. Other tests may include a pregnancy test, cervical Pap smear, erythrocyte sedimentation rate, and fecal occult blood test (Ferri 2014).

7 Conventional Treatment

Many women do not need treatment for uterine fibroids because their fibroids do not cause any noticeable symptoms. For fibroids that require intervention, treatment can be approached medically or surgically (Mitwally 2013).

Medical Treatments

Gonadotropin-releasing hormone agonists. Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide (Lupron) and nafarelin (Synarel) are non-surgical options to treat uterine fibroids (Doherty 2014). They inhibit the production of estrogen and progesterone, resulting in a decrease in fibroid size (Mayo Clinic 2014a). GnRH agonists may be prescribed to shrink fibroids before a hysterectomy or myomectomy, as they appear to improve outcomes and may allow more patients to undergo a less invasive vaginal hysterectomy instead of an abdominal procedure (Lethaby 2001).

Side effects of GnRH agonists are similar to symptoms and complications that can accompany menopause: hot flashes, vaginal dryness, and bone loss (Islam 2013; Magon 2011). Because of this effect on bone, the FDA recommends that GnRH agonists should only be used for the short-term treatment of fibroids – less than six months (Doherty 2014; Gargiulo 1997). The effects of GnRH agonists are reversible, and fibroids tend to return to their pretreatment size approximately six months after drug discontinuation (Golan 1996; Mayo Clinic 2014a). 

Estrogen and progestin therapy. Estrogens and progestins (synthetic, progesterone-like drugs) are commonly combined in oral contraceptive pills. They are often a first-line therapy for patients with excessive bleeding symptoms associated with uterine fibroids; however, they do not reduce fibroid size. In fact, estrogens and progestins may stimulate fibroid growth. Therefore, oral contraceptives should be used with caution in patients with symptoms caused by large fibroids (Doherty 2014).

Tranexamic acid. Tranexamic acid (Lysteda) stabilizes blood clots and is frequently prescribed to prevent excessive menstrual bleeding in women with uterine fibroids who want to maintain fertility and are unable to take oral contraceptives (Doherty 2014; Kumsar 2011; Sweet 2012). It is a well-tolerated drug that works by causing blood clots to form in fibroids, which results in fibroid cell death and eventual fibroid regression. This can cause symptoms of pelvic pain, nausea, fatigue, and low-grade fever (Doherty 2014). 

Non-steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil) or naproxen (Aleve), are commonly prescribed to reduce pain associated with fibroids (UMMC 2014). NSAIDs are also able to reduce menstrual bleeding by approximately 30-40% (Livshits 2010). Women who have heavy menstrual bleeding may have abnormal levels of prostaglandin in their endometrial tissue, and NSAIDs may mitigate uterine bleeding by modulating these prostaglandin levels (Smith 2007; Livshits 2010).

A review of 17 randomized, controlled trials found that NSAIDs were more effective than placebo but less effective than tranexamic acid at reducing excessive menstrual bleeding (Lethaby 2007). NSAIDs reported to be effective for heavy menstrual bleeding include ibuprofen, mefenamic acid (Ponstel), and naproxen (ARHP 2008).

Surgical Procedures

Hysterectomy. Hysterectomy is the surgical removal of the uterus, which can be performed abdominally, vaginally, or laparoscopically (Elsevier BV 2011). Approximately 15% of women who have uterine fibroids undergo hysterectomies (Ferri 2014). One study found that women who underwent hysterectomy reported greater improvements in subjective measures compared to women treated pharmacologically (Kuppermann 2004). 

In abdominal hysterectomy, the uterus is removed through a large incision in the abdomen (Mitwally 2013). In a vaginal hysterectomy, an incision is made in the vagina in order to access and remove the uterus. Compared with abdominal hysterectomy, women report less pain and better physical capability after vaginal hysterectomy (Silva-Filho 2006).

In laparoscopic hysterectomy, small incisions are made in the abdomen, and the uterus can be shredded using a process called power morcellation to allow extraction through the incisions (Nevarez Bernal 2012; Serur 2011). However, the use of power morcellation increases the risk of disseminating undetected (occult) cancer (Mitwally 2013; FDA 2014a; FDA 2014b; Nappi 2014; Della Badia 2010). Given the risks associated with power morcellation, women should discuss other options with their healthcare providers.

Surgical procedures that are less invasive than traditional abdominal hysterectomy and that do not involve power morcellation include minilaparotomy, laparoendoscopic single-site manual morcellation, and vaginal manual morcellation via culdotomy or colpotomy. In these procedures, physicians gain access to the uterus through relatively small incisions in the vagina or abdominal wall. If the target tissue needs to be cut into smaller pieces to be extracted, this can be accomplished manually with a scalpel. However, there is no strong evidence that clearly indicates so-called manual morcellation confers less risk for disseminating hidden cancer than power morcellation, yet the current FDA position only advises against power morcellation (AAGL 2014; FDA 2014b).

Oophorectomy – removal of the ovaries – is sometimes performed at the time of hysterectomy, though controversy exists over whether or not this relatively aggressive treatment is warranted in this context. This procedure may be indicated when there is a high risk of ovarian cancer or of certain types of breast cancer, but bilateral oophorectomy is performed in over 55% of women who undergo hysterectomy for uterine fibroids; a growing concern is the appropriateness of such aggressive treatment in the context of uterine fibroids. Fewer than 5% of women undergoing oophorectomy and hysterectomy actually meet the high-risk criteria for ovarian or breast cancer (Larson 2011; Hickey 2010; Shoupe 2007).

Hysterectomy prevents future menstruation and any chance of recurrent uterine fibroids. However, it also poses potentially serious risks, including damage to the bowel, bladder, or ureter; hemorrhage; infection; wound rupture; blood clots; and pulmonary embolism, a blockage of lung arteries (Khan 2014).

Removal of the ovaries causes an abrupt decline in sex hormones and disrupts the hypothalamic-pituitary-ovarian axis (Rocca 2009). This results in premature menopause, potentially causing symptoms of hot flashes, vaginal dryness, depression, anxiety, and decreased sex drive, and increased risk of heart disease, osteoporosis, and memory loss. These complications are usually treated with hormone replacement therapy (Mayo Clinic 2014c). Some evidence suggests that oophorectomy may do more harm than good (Parker 2014; Parker 2010; Shuster 2008; Rivera 2009). A 24-year follow-up study of over 29 000 women compared the outcomes of women who had either hysterectomies that preserved their ovaries or complete hysterectomies with oophorectomy. While oophorectomy decreased the risk of developing cancer of any kind, including breast cancer and of course ovarian cancer, an increased risk of myocardial infarction (heart attack), stroke, lung cancer, and death from cancer or any cause was noted (Parker 2009). Other studies have confirmed these risks, with one analysis showing that obesity may mediate some of the negative risks of oophorectomy (Duan 2012; Orozco 2014; McCarthy 2012; Parker 2013).

The Dangers of Uterine Power Morcellation

About 500 000 women undergo hysterectomy each year in the United States, making it one of the most common gynecological surgical procedures (CDC 2002; Gaba 2014).

Historically, removal of the uterus through an incision in the abdomen was the standard method of performing a hysterectomy (Baggish 2005; Fram 2013). In recent decades, however, laparoscopic hysterectomy has become increasingly popular (Salama 2013). A laparoscopic operation involves making only a few small holes in the patient’s abdominal wall through which fine surgical instruments are inserted to perform the operation. This approach is more appealing from a cosmetic perspective because it causes considerably less scarring than a traditional abdominal hysterectomy (Reich 1994). However, laparoscopic hysterectomy poses an important obstacle: how to remove the excised uterus from the patient’s abdominal cavity (Kho 2014).

The medical community overcame this barrier by developing a procedure called uterine power morcellation. Power morcellation involves shaving or shredding uterine tissue into smaller pieces that can be extracted with laparoscopic instruments. This procedure uses an electrically powered device to shred the tissue. Although power morcellation offers an effective means of removing the uterus without leaving a large scar, there is a risk of spreading occult/undetected cancerous tissue throughout the abdominal cavity.

During the uterine power morcellation procedure, small pieces of tissue and cellular debris can be spread through the abdominal cavity. If any malignant cells are present in the morcellated uterine tissue, deposition of tissue debris in the abdominal cavity during power morcellation can give rise to disseminated cancer, which has a very poor prognosis (Kho 2014; Park 2011).

Uterine fibroids are benign, but unsuspected uterine sarcoma is present in about one in 350 women undergoing surgery for fibroids (FDA 2014a). In these cases, cancer that was contained within the uterus, and which could have been removed completely via a vaginal or abdominal hysterectomy, may be spread to other parts of the body during power morcellation (Kho 2014; FDA 2014a; Mitwally 2013; Mayo Clinic 2014a; Song 2013).

In light of these findings, on April 17th, 2014 the FDA issued a statement discouraging the use of power morcellation procedures for the removal of uterine fibroids and hysterectomy (FDA 2014a).

Power morcellation runs the risk of other complications as well, including injury to nearby organs and dissemination of fragments of uterine fibroid tissue, which, even if not malignant, can deposit elsewhere in the body and cause problems. For example, if noncancerous fibroid cells are dispersed into the abdominal cavity during power morcellation, they may attach to another abdominal structure, acquire a blood supply, and form a parasitic leiomyoma (Milad 2014; Kho 2014; Takeda 2007; Jebunnaher 2013; Yoshida 2014).

Myomectomy. Myomectomy is the surgical removal of fibroids without removal of the uterus. This procedure may preserve fertility and improve pregnancy outcomes (Mayo Clinic 2013). It can be performed with an abdominal incision; laparoscopically, often with the use of power morcellation; and hysteroscopically, in which the surgical instruments are introduced through the vagina and cervix. The success of myomectomy in treating symptoms associated with fibroids depends on the number and extent of the fibroids. Women who undergo myomectomy have a 10-30% chance of recurrent fibroids within 5 years (Evans 2007; Fauconnier 2000; Rossetti 2001; Desai 2011; Mayo Clinic 2013). 

In rare circumstances, surgical blood loss cannot be controlled or other uterine problems are discovered during a myomectomy procedure, and the surgeon must perform a hysterectomy. Cesarean section deliveries are often performed on women who have had a myomectomy due to risk of complications during vaginal birth (Mayo Clinic 2013).

In abdominal myomectomy, fibroids are removed by making a large incision in the abdomen. Compared with abdominal hysterectomy, abdominal myomectomy is a longer procedure; however, patients typically have significantly less blood loss and, on average, shorter hospital stays (Khan 2014).

Hysteroscopic myomectomy of submucosal fibroids significantly improves the chance of becoming pregnant and decreases the risk of miscarriage. Possible complications include hemorrhage, uterine perforation, cervical laceration, uterine scars, and infertility (Khan 2014; Pritts 2009). 

Laparoscopic myomectomy removes fibroids that deform the uterine cavity, fibroids larger than 3 cm, and multiple fibroids (Desai 2011). While some authors suggest that laparoscopic myomectomy improves a woman’s chance of conceiving and having a successful delivery (Tinelli 2012), it carries risks including blood loss, problems with childbirth, and complications from tissue power morcellation (if the procedure is used) (Mayo Clinic 2013; Buckley 2014).

All three types of myomectomy may cause adhesions (bands of scar tissue), which could block the digestive system, cause abdominal or pelvic pain, or fertility problems. A survey of 414 gynecological surgeons reported that, of surgeries performed for benign conditions, myomectomy posed the second highest risk of adhesion formation behind surgery to treat endometriosis (Wallwiener 2014).

Minimally-Invasive Procedures

Uterine artery embolization. During uterine artery embolization (UAE), a catheter is inserted through the large femoral arteries in the groin and guided into the arteries that supply blood to the fibroid tissue. Chemicals that block blood flow, called embolic agents, are injected into the catheter. The embolic agents cut off the blood supply to the fibroids, causing cells to die and the fibroids to shrink in size (Evans 2007).

Compared to hysterectomy or myomectomy, UAE involves a shorter procedure time, hospital stay, and quicker return to normal activities (Mara 2006; Mara 2008). Complications from UAE can include blood collection outside of vessels (hematoma), bleeding, and infection; further surgeries are required after UAE in approximately 30% of cases (Doherty 2014; Gupta 2012). Post-embolization syndrome, which is characterized by pelvic pain, cramping, nausea, vomiting, fatigue, and mild fever affects most UAE patients, but usually resolves within 48 hours (Mitwally 2013; Doherty 2014). Many authorities do not recommend UAE for women who want to maintain fertility (Doherty 2014; Pron 2005; Cook 2010).

Endometrial ablation and resection of submucosal fibroids. In endometrial ablation, instruments are inserted into the uterus through the vagina to destroy the uterine lining (endometrium). This procedure can remove submucosal fibroids, but not intramural or subserosal fibroids. It reduces menstruation and excessive bleeding, and may cause the complete cessation of menstruation in some women. However, it may contribute to high-risk pregnancies due to injury to the uterine lining, and may increase risk of perforation of the uterine wall, pain, bleeding, infection, or neighboring organ damage (Mayo Clinic 2012). 

Magnetic resonance-guided focused ultrasound surgery. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) (ExAblate 2000 system) is a non-invasive procedure that was approved by the FDA in 2004 for the treatment of uterine fibroids (Khan 2014). During the procedure, a patient is placed into an MRI machine to visualize fibroids and surrounding organs, while high-energy ultrasound waves are directed at the fibroid, causing an increase in temperature and tissue damage. Clinical studies show that 70-80% of women have improvements in clinical symptoms after MRgFUS (Roberts 2008; Abdullah 2010). However, these improvements may be temporary as one study found 71% of women experienced symptom reduction at six months, but the proportion declined to 51% at 12 months (Stewart 2006).

MRgFUS is an outpatient treatment that does not require general anesthesia, allowing patients to return to their normal routine in one or two days, compared to six weeks recovery or more for hysterectomy and 2-4 weeks for myomectomy. Side effects appear to be minimal, though damage to neighboring organs is possible but rare (Abdullah 2010). Only patients whose fibroids are located immediately beneath the frontal abdominal wall, and who have no bowel interference or prior scarring around the target area, are eligible for MRgFUS (Khan 2014). As of 2012, MRgFUS was not recommended for women who want to maintain their fertility (ASRM 2012b), though successful pregnancies have occurred following treatment (Rabinovici 2010).

8 Novel and Emerging Strategies

Selective Progesterone Receptor Modulators

The hormone progesterone is an important contributor to uterine fibroid development. Fibroids have higher levels of the progesterone receptor than the surrounding normal tissue, and inhibition of the progesterone receptor decreases fibroid growth in animal models. Drugs that are selective progesterone receptor modulators (SPRMs) include ulipristal acetate (Ella) and mifepristone (Mifeprex). They interfere with the progesterone receptor and are entering clinical practice for the treatment of uterine fibroids (Chwalisz 2005; Whitaker 2014; Donnez, Donnez 2014; Islam 2013).

Ulipristal acetate was approved by the FDA in 2010 as an emergency contraceptive (Kim 2011; Watson Pharma Inc. 2010). It has been approved in Europe (Esmya) and Canada (Fibristal) for pre-surgical medical treatment of uterine fibroids, to be used for no more than three months (Delev 2013; Health Canada 2014; Actavis 2013). In a trial comparing ulipristal acetate to placebo, the drug effectively controlled bleeding, shrank fibroids, and had a similar side effect profile to placebo (Donnez, Tatarchuk 2012). Another trial compared ulipristal acetate to the GnRH agonist leuprolide and found them similarly effective, though ulipristal acetate had a lower incidence of moderate-to-severe hot flashes (Donnez, Tomaszewski 2012). While it has not been approved for the treatment of fibroids in the United States, ulipristal acetate 5 mg is considered a new standard of medical treatment for uterine fibroids in regions where it is approved (Donnez, Donnez 2014; Whitaker 2014; Biglia 2014).

Mifepristone was approved by the FDA in 2000 for early termination of pregnancy up to day 49 after conception (Danco Laboratories 2009; Allen 2009). An open-label trial in 33 women with fibroids assessed the effects of a 3-month treatment with mifepristone, delivered as a vaginal suppository. Treatment was well tolerated, with no serious side effects, and resulted in a significant decrease in fibroid volume and bleeding as well as a significant increase in quality of life score (Yerushalmi 2014). However, an earlier review of three randomized controlled trials concluded that oral mifepristone did not decrease fibroid or uterine volume, but did decrease heavy menstrual bleeding and improve quality of life (Tristan 2012). Side effects of mifepristone may include hot flashes and changes in liver enzyme activity. Additional long-term, randomized trials are required to determine if oral or vaginally delivered mifepristone effectively treats uterine fibroids (Doherty 2014). 

SPRM-Induced Endometrial Changes

The endometrium – the inner lining of the uterus – plays an important role in preparation for pregnancy.  During a menstrual cycle, increased levels of estrogen cause the endometrium to thicken to allow a fertilized egg to become implanted. After ovulation, progesterone levels increase to further prepare the endometrium to receive the fertilized egg. If the egg does not become fertilized, estrogen and progesterone levels decrease, causing the endometrial lining to shed, which causes menstruation (ACOG 2012). 

If estrogen levels increase or progesterone levels decrease, the endometrial lining may thicken without being shed. This is known as endometrial hyperplasia. Endometrial hyperplasia often occurs after menopause when progesterone levels decrease, or in situations that lead to increased estrogen levels, such as the use of medication that mimics estrogen or the administration of high-dose estrogen without progesterone after menopause (Figueroa-Casas 2001; Carlson 2012; ACOG 2012). If endometrial hyperplasia is not treated, endometrial cancer may develop in 8-29% of cases (ACS 2014b).

Early studies of SPRMs, particularly mifepristone, found they cause endometrial hyperplasia. However, additional studies determined this response is dose-dependent. Higher doses of mifepristone can induce hyperplasia, whereas lower doses cause endometrial changes that are reversible. Pathologists should be aware of endometrial changes that can occur with SPRM treatment and not misdiagnose these alterations as hyperplasia (Doherty 2014).

Aromatase Inhibitors

Fibroid tissue contains high levels of aromatase, the enzyme that converts testosterone into estrogen. Thus, blocking aromatase to reduce estrogen levels may be an effective treatment for uterine fibroids (Ishikawa 2009). The aromatase inhibitors letrozole (Femara) and anastrozole (Arimidex) are approved for the treatment of hormone receptor-positive breast cancer (Sanford 2008; Knoche 1999; Cohen 2002) and are currently being studied for the treatment of uterine fibroids (Khan 2014).  

In a small study of 16 premenopausal women, letrozole decreased fibroid volume and improved heavy menstrual bleeding (Gurates 2008). Another study in 20 women showed similar effects (Hilario 2009). In a randomized study in 70 women, letrozole reduced fibroid volume by 45.6%, while the GnRH agonist triptorelin (Trelstar) decreased fibroid volume by 33.2% (Parsanezhad 2010). Anastrozole treatment in 20 women reduced fibroid volume by an average of 9.3% and reduced the amount of menstrual bleeding (Hilario 2009).

Aromatase inhibitors may promote the formation of ovarian cysts. One study on 16 patients reported that 56% of women developed ovarian cysts after letrozole treatment (Gurates 2008), though cyst formation can be prevented by co-treatment with estrogen, progesterone, or a GnRH agonist (Doherty 2014). An alternative method of aromatase inhibitor treatment may be low-dose letrozole; reductions in fibroid volume without hot flashes or ovarian cysts have been reported (Parsanezhad 2010; Doherty 2014). Additional studies are needed to determine if long-term, low-dose letrozole is safe for women with uterine fibroids (Islam 2013; Doherty 2014).

Growth Factor Inhibitors

Certain growth factors, which are a type of molecular cell messenger, promote the development of fibroids. Several inhibitors of growth factor signaling pathways have shown potential efficacy for the treatment of uterine fibroids in laboratory and case studies. However, these agents have not yet been adequately studied in clinical trials (Doherty 2014).

Insulin-like growth factor (IGF) signaling contributes to the initiation and progression of fibroid growth, and uterine fibroids have higher levels, compared to normal uterine tissue, of the receptors for IGF-1 and IGF-2. Lanreotide (Somatuline Depot) is a medication that blocks the release of growth factors such as IGF (Chanson 2008). A small study in seven women with fibroids reported that lanreotide reduced fibroid volume by an average of 42% over a 3-month period (Khan 2014). In December 2014 lanreotide was approved by the FDA for the treatment of certain gastroenteropancreatic neuroendocrine tumors; it had previously been approved for long-term treatment of acromegaly in patients who did not respond to, or were not candidates for, other types of treatment (FDA 2014c).

VizAblate and Acessa

The VizAblate and Acessa systems are new, noninvasive instruments that remove fibroids via ablation. The VizAblate device (Gynesonics, Inc.) combines real-time sonography to visualize the endometrial cavity with radiofrequencies to treat uterine fibroids in a single device. The instrument is inserted through the cervix, into the uterus, and allows the patient to be treated without incision or general anesthesia (Waltman 2011; Garza-Leal 2011). While the VizAblate device is not currently available as a treatment option in the United States, the results of an international multi-center 12-month study were published in late 2014. This study examined the use of VizAblate as a treatment for 50 women with symptomatic uterine fibroids: a total of 92 fibroids were treated. Three months after treatment, perfused fibroid volume decreased significantly, by an average of 68.8%; after six months, subjective symptom scores decreased by roughly 60%, while quality of life scores increased more than 2.5-fold compared to before treatment. Further results from this study showed that after 12 months there was a median 76% reduction in fibroid volume and a 73% median reduction in menstrual blood loss. The authors reported a good safety profile for the procedure (Gynesonics 2014a; Gynesonics 2014b; Reuters 2014a; Bongers 2014).

The Acessa system, which is available in the United States, also combines ultrasound visualization and radiofrequency ablation (Brucker 2014). Two ports are inserted surgically through the abdomen and into the uterus to locate and target fibroids (Guido 2013; Halt Medical Inc. 2014). A study compared Acessa to standard laparoscopic myomectomy in 51 women with fibroids. Acessa treatment resulted in a significant reduction in hospitalization time and blood loss, and a significant increase in the number of fibroids imaged and excised. Complications following the Acessa procedure were minimal. A 2014 paper presented the results of two phase II and one phase III multi-center trial of the Acessa system for the treatment of symptomatic uterine fibroids. Combined symptom severity scores decreased by nearly 84%, quality of life scores nearly doubled, and mean uterine volume decreased by 24%, all significant outcomes. The rate of side effects and complications was low, and four women became pregnant in the year following the procedure (Brucker 2014; Galen 2014).

Uterine Artery Embolization via Transradial Access

The standard uterine artery embolization (UAE) procedure uses arteries in the groin for treatment access, which can result in significant postsurgical pain (Resnick 2014). A 2014 publication reported a novel procedure using access sites in the wrist (“transradial”), similar to treatment procedures for heart conditions (Resnick 2014; Interventional News 2014). The new UAE technique was performed on 29 women, and the procedure was technically successful in all patients with no major or minor complications reported (Resnick 2014). UAE via transradial access reduces the incidence of pain and complications related to blood loss compared to conventional UAE technique. Patients are able to walk immediately after treatment. Additional studies are needed to validate the efficacy and safety of this procedure before it becomes widely available (Interventional News 2014).

Metformin Inhibits Uterine Fibroid Cell Growth

Due to its proven ability to regulate blood glucose levels, metformin is the most frequently used antidiabetic drug in the world (Li, Takeda 2013). Metformin also possesses other properties that may be beneficial for the treatment of uterine fibroids (Beck 2013; Luo 2010; Hawley 2002). In a laboratory study, scientists measured the rate of proliferation of uterine fibroid cells following exposure to metformin. They found that “Metformin potently inhibited [uterine fibroid cell] proliferation in a dose-dependent manner.” The researchers then analyzed the molecular mechanisms by which metformin exerted this powerful effect. Their investigation revealed that metformin’s mediation of cellular pathways involved in cell proliferation may account for the beneficial effect upon uterine fibroid cells (Li, Takeda 2013). ​Metformin is thought to retard the growth of various cancers by inhibiting a molecular pathway involved in cell survival, as well as through its ability to modulate insulin signaling (Beck 2013; Hawley 2002).

9 Dietary and Lifestyle Considerations


Several epidemiological studies have analyzed associations between dietary factors and fibroid development. Women who consume greater quantities of vegetables, fruits, and dairy products appear to have a decreased risk of developing fibroids (He 2013; Wise 2011; Wise 2010) whereas women who consume more beef, ham, or other red meats may have an increased risk of developing fibroids (Trivedi 2009; Chiaffarino 1999).

Glycemic index is a measure of a food’s ability to increase blood glucose levels compared to a carbohydrate such as glucose or white bread. Glycemic load is a measure arrived at by multiplying the glycemic index of a serving of food by the grams of carbohydrates it contains. An analysis of over 21 000 African-American women reported that those with a higher dietary glycemic index or glycemic load may have a slightly increased risk of developing fibroids. Additional analysis found that African-American women under the age of 35 years with a high glycemic load diet also had an increased risk of uterine fibroids (Radin 2010).


Women who exercise appear to have a reduced risk of developing fibroids (Elsevier BV 2011). A dose-response pattern is apparent, such that women who exercise seven hours or more per week reduce their risk more than women who exercise two hours or less per week (Baird 2007). The effects of exercise on fibroid growth may be due to loss of body fat. Studies have shown that women who exercise and reduce their body fat by more than 2% have reduced levels of the sex hormones testosterone, estrone, and estradiol (Brown 2012). Exercise also reduces levels of insulin and IGFs (Aarnio 2001). These combined effects may decrease a woman’s risk of developing uterine fibroids (Elsevier BV 2011).

10 Nutrients

Green Tea and Epigallocatechin Gallate

Epigallocatechin gallate (EGCG), a polyphenol found in green tea, has antioxidant, anti-inflammatory, and anti-tumorigenic properties, and shows significant promise for the treatment of uterine fibroids (Islam 2013; Chatterjee 2012). A randomized, placebo-controlled trial studied the effect of 800 mg green tea extract, containing 45% EGCG (360 mg EGCG per day), in 39 women with symptomatic fibroids. The 22 women who took green tea extract daily for four months had a significant 32.6% reduction in fibroid volume and a significant 32.4% reduction in severity of fibroid symptoms. The green tea extract also led to significant improvements in anemia, blood loss, and quality of life. There were no reported adverse events following treatment (Roshdy 2013). EGCG also inhibited the growth of new blood vessels that supply malignant tumors with nutrients in laboratory and animal models of cancer (Carlson 2007; Khan 2010), inhibited the growth of uterine fibroid cells, and induced uterine fibroid cell death in a laboratory study (Zhang 2010). Additionally, EGCG significantly reduced the size and number of fibroids in an animal model (Ozercan 2008).

The combination of EGCG with vitamin D and a small amount of vitamin B6 has also been studied in two clinical trials. The role vitamin D may play in fibroids is discussed at length below. Vitamin B6 has been extensively studied and shown to be of benefit for the management of premenstrual syndrome (Kiani 2016).

In the first pilot study, 30 women of reproductive age with at least one fibroid ≥2 cm3 were randomized to treatment with a combination of 5 mg vitamin B6, 25 mcg (1,000 IU) vitamin D, and 150 mg EGCG taken twice daily for four months, or no treatment. At four months, there was a significant 34.7% reduction of fibroid volume in the intervention group versus a 6.9% increase in the control group. And questionnaires assessing quality of life and symptom severity revealed significant improvements in the intervention group versus control (Porcaro 2020). In the second, larger trial, 95 women with at least one fibroid <4 cm in diameter received either the same intervention or no treatment for four months. After four months, total fibroid volume decreased by about 38% in the intervention group versus a 5.5% increase in the control group. In addition, a score relating to health status and quality of life significantly improved in the intervention group (Miriello 2021). 

Vitamin D

Several studies have reported that women who have lower serum levels of vitamin D are more likely to develop uterine fibroids. In one study, there was also a significant relationship between vitamin D levels and fibroid size: women with lower vitamin D had larger fibroids, and those with higher vitamin D had smaller fibroids. This finding was especially evident among black women and present as a trend among white women. Another study found that women with sufficient vitamin D levels, defined in this study as greater than 20 ng/mL, had an estimated 32% lower odds of having fibroids compared to those with vitamin D levels below 20 ng/mL. Yet another study reported that women with vitamin D deficiency had a significant 2.4-fold greater odds of having uterine fibroids (Baird 2013; Sabry 2013; Paffoni 2013). The majority of fibroids have low levels of the vitamin D receptor compared to surrounding normal tissue. Vitamin D decreases levels of proteins known to contribute to fibroid formation and inhibits the replication of fibroid cells (Halder 2013; Sharan 2011). In a laboratory study, the active form of vitamin D, at normal concentrations, significantly inhibited growth in uterine fibroid cells by 12% compared with controls. This effect was stronger at higher concentrations; the greatest concentration of activated vitamin D significantly suppressed growth by 62% (Bläuer 2009). Furthermore, a preclinical experiment found that treatment of mice with vitamin D3, at a dosage equivalent to 124 IU/day for a 175 lb human, or paricalcitol (Zemplar), an analog of vitamin D3, resulted in a significant reduction in fibroid size (Halder 2014). These data suggest that vitamin D may potentially be an effective agent to treat fibroids (Sabry 2012). Life Extension suggests that most people maintain blood levels of 25-hydroxyvitamin D between 50 and 80 ng/mL for optimal health. 

Two clinical trials have assessed the effect of vitamin D as a monotherapy on uterine fibroids. In a sample of 108 vitamin D insufficient (< 30 ng/mL) women diagnosed with “small burden” fibroids (having a diameter ≤50 mm, no more than four fibroids, and not requiring other medical treatment), participants were offered supplementation of 1,250 mcg (50,000 IU) cholecalciferol once weekly for eight weeks followed by maintenance therapy of 50 mcg (2,000 IU) daily for a year. Those who refused the therapy or were non-compliant were considered the control group (n=55). Fibroid characteristics and symptoms, as well as vitamin D levels, were evaluated 12 months after initial diagnosis. In the intervention group, in addition to a statistically significant increase in vitamin D levels (approx. 20 vs. 31  ng/mL), there was a lower rate of surgical or medical treatment due to fibroid progression (about 13% vs. 31%). And there was no change in the size of fibroids in the vitamin D group versus a significant increase in control subjects (Ciavattini 2016). In a randomized clinical trial, which included 60 women with uterine fibroids and vitamin D insufficiency (< 30 ng/mL), oral supplementation with 1,250 mcg (50,000 IU) cholecalciferol weekly for 12 weeks did not significantly reduce fibroid volume. However, there was a significant increase in fibroid volume in the placebo group suggesting vitamin D may have played a role in preventing fibroid growth. Vitamin D levels in the intervention group increased from a baseline of about 11 ng/mL to about 31 ng/mL during the intervention period (Arjeh 2020). It is unknown if achieving higher vitamin D levels would have provided further benefit because, in both of these studies, women in the vitamin D groups barely exceeded the insufficiency threshold after the intervention. Life Extension suggests that most people maintain blood levels of 25-hydroxyvitamin D between 50 and 80 ng/mL for optimal health. 


Curcumin has been investigated as a potential therapeutic agent for uterine fibroids. In a laboratory setting, curcumin inhibited uterine fibroid cell growth (Tsuiji 2011). Curcumin also decreased the level of fibronectin, an important component of the extracellular matrix that contributes to fibroid progression, without significant effects on normal uterine muscle tissue (Malik 2009). Several growth factors are known to be important contributors to fibroid growth, including IGFs, fibroblast growth factors, and transforming growth factors. Curcumin has been shown to inhibit the secretion of IGF-1 in breast cancer cells; block fibroblast growth factor-2-induced blood vessel growth; and inhibit transforming growth factor-beta signaling in a variety of cells, including liver and kidney cells (Xia 2007; Mohan 2000; Li, Wang 2013; Chen, Geng 2014).

Chinese Herbal Medicine Cinnamon and Poria Formula

Traditionally referred to as Gui Zhi Fu Ling, Cinnamon and Poria Formula has been used in China to treat a range of women’s symptoms since the 3rd century AD. Cinnamon and Poria Formula is composed of a combination of 5 herbs: Ramulus Cinnamomi, Poria, Semen Persicae, Cortex Moutan, and Radix Paeoniae Rubra or Radix Paeoniae Alba (Chen, Han 2014; Liu 2013).

Cinnamon and Poria Formula is commonly administered as a capsule, tablet, or liquid herbal extract. Numerous studies have analyzed the effects of the formula on fibroids and their associated symptoms. A comprehensive review of 38 randomized controlled trials with a total of 3816 patients reported that Cinnamon and Poria Formula plus mifepristone is more effective at reducing fibroid volume than mifepristone alone (Chen, Han 2014). These results support those reached in a separate analysis that analyzed cumulative evidence from seven trials. That analysis found that Cinnamon and Poria Formula, either alone or in combination with mifepristone, also appeared to significantly improve symptoms of painful periods. Treatment with Cinnamon and Poria Formula posed minimal risks, and no serious side effects were reported in any of the trials (Liu 2013). It is important to note that 23 of 38 trials in the meta-analysis did not include safety data, and many of the studies included had a small number of participants and did not use a rigorous methodology. Therefore, definitive conclusions about the effectiveness of Cinnamon and Poria Formula cannot be reached based on currently available research (Chen, Han 2014).

Cimicifuga racemosa (Black Cohosh) Extract

Black Cohosh is an herb commonly used to treat menopausal symptoms. A 2014 trial assessed the effect of a 40 mg black cohosh extract in 34 women with menopausal symptoms and fibroids. In this trial, a different group of 28 women took the synthetic estrogen tibolone (Livial), a drug that is not approved in the United States. In 70.1% of women in the black cohosh group, fibroids decreased in size an average of 30.3% after a 12-week treatment period. In the tibolone group, fibroid size increased by 4.7% during the same time period (Xi 2014).

Tripterygium wilfordii Hook. f. Extract – Benefits and Potential Risks

Tripterygium wilfordii Hook. f., an extract from the Chinese herb Tripterygium wilfordii, is frequently used in China to treat uterine fibroids. Several clinical trials showed that Tripterygium wilfordii Hook. f. extract significantly reduced fibroid volume and heavy menstrual bleeding after 3-4 months of treatment. A 2005 paper reported on a study in 124 women, half of whom received 40 mg Tripterygium wilfordii Hook. f. extract daily for 3-6 months while the other half received mifepristone. The authors reported a significant decrease in fibroid size after 3-4 months, with a more pronounced effect detectable by 5-6 months, based on ultrasound examination (Fu 2005). In a similar 3-month trial comparing Tripterygium wilfordii Hook. f. extract to mifepristone in 62 women, the authors reported a significant reduction in fibroid size (Wen 2005). In both of these trials, results of the herbal extract were superior to those achieved by mifepristone. An earlier trial of Tripterygium wilfordii Hook f. extract found that it significantly decreased fibroid size after 3-4 months of treatment, with a somewhat higher percentage of patients responding after 5-6 months. The decrease in fibroid size with Tripterygium wilfordii Hook. f. treatment was time-dependent; the response was nearly double after 5-6 months compared to 3-4 months. It is worth noting that 38% of patients did not have a menstrual cycle during the treatment, and Tripterygium wilfordii Hook. f. treatment decreased average estradiol and progesterone levels (Gao 2000).

Despite these promising findings, several reports of severe toxicity and even death associated with the use of Tripterygium wilfordii Hook. f. are available, and it appears the dose required for clinical effectiveness is very close to the dose required to cause toxicity (Huang 2009; Wang 1989). Another report linked Tripterygium wilfordii Hook. f. use to low bone mineral density in women (Huang 2000).

Life Extension does not suggest the use of Tripterygium wilfordii outside of a clinical setting. If a healthcare practitioner decides to use this therapy with patients, only a standardized extract of the skinned root should be used, as other parts of the plant are highly toxic (NCCAM 2012).

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

AAGL. Advancing Minimally Invasive Gynecology Worldwide. Morcellation During Uterine Tissue Extraction. Available at: http://www.aagl.org/wp-content/uploads/2014/05/Tissue_Extraction_TFR.pdf. 5/6/2014. Accessed 12/16/2014.

Aarnio P, Lauritsen T, Dela F. Insulin secretion and glucose kinetics during exercise with and without pharmacological alpha(1)- and alpha(2)-receptor blockade. Diabetes. Aug 2001;50(8):1834-1843.

Abdullah B, Subramaniam R, Omar S, Wragg P, Ramli N, Wui A, . . . Yusof Y. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) treatment for uterine fibroids. Biomedical imaging and intervention journal. Apr-Jun 2010;6(2):e15.

ACOG. Saline infusion sonohysterography. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. Jan 2004;84(1):95-98.

ACOG. American College of Obstetricians and Gynecologists. Frequently Asked Questions page. Hysteroscopy. Available at: http://www.acog.org/~/media/For%20Patients/faq084.pdf. 10/2011. Accessed 10/10/2014.

ACOG. American College of Obstetricians and Gynecologists. Endometrial Hyperplasia. Available at: https://www.acog.org/~/media/For%20Patients/faq147.pdf?dmc=1&ts=20140810T2133337184. Copyright February 2012. Accessed 8/10/14.

ACS. American Cancer Society. Endometrial (Uterine) Cancer. Available at: http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-risk-factors. Last updated 2/3/14b. Accessed 8/10/14.

ACS. American Cancer Society. Uterine Sarcoma. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003145-pdf.pdf. Copyright © 2014a. Accessed 6/22/14.

Actavis. Actavis Specialty Pharmaceuticals Co. Media Press Releases page. First-ever medical treatment for uterine fibroids - FIBRISTAL - Now available in Canada. Available at: http://www.actavis.ca/specialty/en/news/fibristal_for_uterine_fibroids.htm. 7/23/2013. Accessed 10/10/2014.

A.D.A.M. MedlinePlus online. Hysteroscopy. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/007571.htm. Last updated 11/16/2012. Accessed 10/10/2014.

Aharoni A, Reiter A, Golan D, Paltiely Y, Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. British journal of obstetrics and gynaecology. 1988;95(5):510-513.

Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics & gynecology. Summer 2009;2(3):159-168.

Arjeh S, et al. Effect of oral consumption of vitamin D on uterine fibroids: A randomized clinical trial. Complement Ther Clin Pract. 2020;39: 101159.

ASRM. American Society for Reproductive Medicine. Laparoscopy and Hysteroscopy: A Guide for Patients. Available at: http://www.reproductivefacts.org/uploadedFiles/ASRM_Content/Resources/Patient_Resources/Fact_Sheets_and_Info_Booklets/laparoscopy.pdf. Copyright 2012a. Accessed 10/10/2014.

ASRM. American Society for Reproductive Medicine. Fact Sheet From ReproductiveFacts.org: Treatment of Uterine Fibroids. Available at: http://www.reproductivefacts.org/FACTSHEET_Treatment_of_Uterine_Fibroids/. Last updated 2012b. Accessed 8/10/14.

ARHP. Association of Reproductive Health Professionals. Abnormal Uterine Bleeding. Available at: http://www.arhp.org/publications-and-resources/clinical-fact-sheets/abnormal-uterine-bleeding. Last updated July 2008. Accessed 8/9/14.

Baggish MS. Total and subtotal abdominal hysterectomy. Best practice & research. Clinical obstetrics & gynaecology. Jun 2005;19(3):333-356.

Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. Association of physical activity with development of uterine leiomyoma. American journal of epidemiology. Jan 15 2007;165(2):157-163.

Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology (Cambridge, Mass.). May 2013;24(3):447-453.

Beck E, Scheen AJ. [Metformin, an antidiabetic molecule with anti-cancer properties]. Revue medicale de Liege. Sep 2013;68(9):444-449.

Biglia N, Carinelli S, Maiorana A, D'Alonzo M, Lo Monte G, Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug design, development and therapy. 2014;8:285-292.

Bläuer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertility and sterility. 2009;91(5):1919-1925.

Bongers M, Brölmann H, Gupta J, et al. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate® System: three- and six-month endpoint results from the FAST-EU study. Gynecological Surgery. 11/28/2014.

Boynton-Jarrett R, Rich-Edwards J, Malspeis S, Missmer SA, Wright R. A prospective study of hypertension and risk of uterine leiomyomata. American journal of epidemiology. Apr 1 2005;161(7):628-638.

Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Comprehensive Physiology. Oct 2012;2(4):2775-2809.

Brucker SY, Hahn M, Kraemer D, Taran FA, Isaacson KB, Kramer B. Laparoscopic radiofrequency volumetric thermal ablation of fibroids versus laparoscopic myomectomy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. Jun 2014;125(3):261-265.

Buckley V, Nesbitt-Hawes EM, Atkinson P, Won HR, Deans R, Burton A, . . . Abbott JA. Laparoscopic Myomectomy: clinical outcomes and comparative evidence. Journal of minimally invasive gynecology. Aug 9 2014.

Bulun SE. Uterine Fibroids. New England Journal of Medicine. 2013;369(14):1344-1355.

Carlson JR, Bauer BA, Vincent A, Limburg PJ, Wilson T. Reading the tea leaves: anticarcinogenic properties of (-)-epigallocatechin-3-gallate. Mayo Clinic proceedings. Jun 2007;82(6):725-732.

Carlson MJ, Thiel KW, Yang S, Leslie KK. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discovery medicine. Sep 2012;14(76):215-222.

CDC. Centers for Disease Control and Prevention. Hysterectomy Surveillance --- United States, 1994--1999. 7/12/2002. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5105a1.htm. Accessed 4/25/2014.

Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clinical endocrinology. Aug 2008;69(2):299-305.

Chatterjee P, Chandra S, Dey P, Bhattacharya S. Evaluation of anti-inflammatory effects of green tea and black tea: A comparative in vitro study. Journal of advanced pharmaceutical technology & research. Apr 2012;3(2):136-138.

Chen N, Geng Q, Zheng J, He S, Huo X, Sun X. Suppression of the TGF-beta/Smad signaling pathway and inhibition of hepatic stellate cell proliferation play a role in the hepatoprotective effects of curcumin against alcohol-induced hepatic fibrosis. International journal of molecular medicine. Jul 25 2014.

Chen NN, Han M, Yang H, Yang GY, Wang YY, Wu XK, Liu JP. Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: a systematic review of randomised clinical trials. BMC complementary and alternative medicine. 2014;14:2.

Chiaffarino F, Parazzini F, La Vecchia C, Chatenoud L, Di Cintio E, Marsico S. Diet and uterine myomas. Obstetrics and gynecology. Sep 1999;94(3):395-398.

Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine reviews. May 2005;26(3):423-438.

Ciavattini A, Di Giuseppe J, Stortoni P, Montik N, Giannubilo SR, Litta P, . . . Ciarmela P. Uterine Fibroids: Pathogenesis and Interactions with Endometrium and Endomyometrial Junction. Obstetrics and gynecology international. 2013;2013:173184.

Ciavattini A, et al. Hypovitaminosis D and "small burden" uterine fibroids: Opportunity for a vitamin D supplementation. Medicine (Baltimore). 2016;95(52): e5698.

Clement PB. Pure mesenchymal tumors. In: Clement PB, Young RH, eds. Tumors and tumors – like lesions of the uterine corpus and cervix. New York: Churchill Livingston: 1993, pp. 265-328.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. Mar 2002;8(3):665-669.

Cook H, Ezzati M, Segars JH, McCarthy K. The impact of uterine leiomyomas on reproductive outcomes. Minerva ginecologica. Jun 2010;62(3):225-236.

Danco Laboratories. Mifeprex Prescribing Information. Available at: http://earlyoptionpill.com/what-is-mifeprex/. Last updated 4/22/09. Accessed 8/10/14.

Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM: High cululative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.

Delev DP. Ulipristal acetate--a review of the new therapeutic indications and future prospects. Folia medica. Jul-Dec 2013;55(3-4):5-10.

Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy. Journal of minimally invasive gynecology. Nov-Dec 2010;17(6):791-793.

Desai P, Patel P. Fibroids, infertility and laparoscopic myomectomy. Journal of gynecological endoscopy and surgery. Jan 2011;2(1):36-42.

Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive sciences (Thousand Oaks, Calif.). May 12 2014.

Donnez J, Donnez O, Dolmans MM. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertility and sterility. Sep 2014;102(3):640-648.

Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, . . . Loumaye E. Ulipristal acetate versus placebo for fibroid treatment before surgery. The New England journal of medicine. Feb 2 2012;366(5):409-420.

Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, . . . Loumaye E. Ulipristal acetate versus leuprolide acetate for uterine fibroids. The New England journal of medicine. Feb 2 2012;366(5):421-432.

Duan L, Xu X, Koebnick C, Lacey Jr JV, Sullivan-Halley J, Templeman C, . . . Henderson KD. Bilateral oophorectomy is not associated with increased mortality: the California Teachers Study. Fertility and sterility. 1/2012;97(1):111-117.

Ekpo GE, Kao CN, Rosen MP, Sternfeld B, Cedars M. Insulin resistance and uterine fibroids: is there an association and does this vary across race/ethnic groups? Fertility and sterility. 2013;100(3):S35.

Elsevier BV. First Consult. Fibroids (uterine myomas). Available at www.clinicalkey.com. Updated 3/9/2011. Accessed 6/3/2014.

Eltoukhi HM, Modi MN, Weston M, Armstrong AY, Stewart EA. The health disparities of uterine fibroid tumors for African American women: a public health issue. American journal of obstetrics and gynecology. Mar 2014;210(3):194-199.

Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. American family physician. May 15 2007;75(10):1503-1508.

Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Human reproduction update. Nov-Dec 2000;6(6):595-602.

FDA. US Food and Drug Administration. FDA News Release: FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids. 4/17/2014a. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm Accessed 4/25/2014.

FDA. US Food and Drug Administration. Medical Devices page. UPDATED Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm. 11/24/2014b. Accessed 12/16/2014.

FDA. US Food and Drug Administration. Drugs page. Lanreotide. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427065.htm. Accessed 12/18/2014c.

Ferri FF. Ferri's Clinical Advisor. Uterine Fibroids. Available at: www.clinicalkey.com. Copyright © 2014. Accessed 6/3/2014.

Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy. Menopause (New York, N.Y.). Nov-Dec 2001;8(6):420-423.

Fram KM, Sumrein IM. Laparoscopic versus abdominal hysterectomy in the treatment of endometrial cancer. Saudi medical journal. Jan 2013;34(1):11-18.

Fu WJ, Ni J, Zheng LJ, et al. Observation on therapeutic effects of small dosage of Tripterygium Wilfordii Hook for treatment of uterine leiomyoma. Journal of Hebei North University (Medical Edition). 2005;22(1):46-8.

Gaba ND, Polite FG, Keller JM, Young AE. To err is human; to provide safe, quality, and cost-effective hysterectomy is divine! Clinical obstetrics and gynecology. Mar 2014;57(1):128-139.

Galen DI, Pemueller RR, Leal JGG, et al. Laparoscopic Radiofrequency Fibroid Ablation: Phase II and Phase III Results. JSLS. 2014;18:182-190.

Gao Y, Chen D. [Clinical study on effect of Tripterygium wilfordii Hook. f. on uterin leiomyoma]. Zhonghua fu chan ke za zhi. Jul 2000;35(7):430-432.

Gargiulo AR, Hornstein MD. The role of GnRH agonists plus add-back therapy in the treatment of endometriosis. Seminars in reproductive endocrinology. 1997;15(3):273-284.

Garza-Leal JG, Toub D, Leon IH, Saenz LC, Uecker D, Munrow M, . . . Coad J. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting. Gynecological surgery. 2011;8:327-334.

Golan A. GnRH analogues in the treatment of uterine fibroids. Human reproduction (Oxford, England). Nov 1996;11 Suppl 3:33-41.

Goldsmith LT, Weiss G. Relaxin in human pregnancy. Annals of the New York Academy of Sciences. Apr 2009;1160:130-135.

Gonsalves C. Uterine artery embolization for treatment of symptomatic fibroids. Seminars in interventional radiology. Dec 2008;25(4):369-377.

Guido RS, Macer JA, Abbott K, Falls JL, Tilley IB, Chudnoff SG. Radiofrequency volumetric thermal ablation of fibroids: a prospective, clinical analysis of two years' outcome from the Halt trial. Health and quality of life outcomes. 2013;11:139.

Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. The Cochrane database of systematic reviews. 2012;5:Cd005073.

Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reproductive biomedicine online. Oct 2008;17(4):569-574.

Gynesonics. Fibroid Ablation Study (FAST-EU). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014a. Accessed 7/3/14. Available at: http://clinicaltrials.gov/ct2/show/NCT01226290. NLM Identifier: NCT01226290.

Gynesonics. Gynesonics accounces another peer-reviewed publication and presentation of significant international clinical experience with vizablate technology for symptomatic uterine fibroids. Available at: http://gynesonics.com/wp-content/uploads/2014/12/Press-Release-FAST-EU-6-Month-Results-and-2014-AAGL-December-9-2014-FINAL.pdf. Accessed 12/18/2014b.

Halder SK, Osteen KG, Al-Hendy A. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biology of reproduction. Dec 2013;89(6):150.

Halder SK, Sharan C, Al-Hendy O, Al-Hendy A. Paricalcitol, a Vitamin D Receptor Activator, Inhibits Tumor Formation in a Murine Model of Uterine Fibroids. Reproductive sciences (Thousand Oaks, Calif.). Jun 12 2014.

Halt Medical Inc. The Acessa Procedure. Copyright 2014. Available at: http://www.haltmedical.com/procedure-video. Accessed 7/3/14.

Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. Aug 2002;51(8):2420-2425.

He Y, Zeng Q, Dong S, Qin L, Li G, Wang P. Associations between uterine fibroids and lifestyles including diet, physical activity and stress: a case-control study in China. Asia Pacific journal of clinical nutrition. 2013;22(1):109-117.

Health Canada. Drugs and Health Products page. FIBRISTAL. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_fibristal_156861-eng.php. Last updated 4/28/2014. Accessed 10/10/2014.

Hickey M, Ambekar M, Hammond I. Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Human reproduction update. Mar-Apr 2010;16(2):131-141.

Hilario SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertility and sterility. Jan 2009;91(1):240-243.

Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Human molecular genetics. Apr 15 2007;16 Spec No 1:R7-13.

Huang GZ, Li L, Liu L. [Pathological study on autopsy died of Tripterygium intoxication – report of 4 cases]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Feb;29(2):165-8.

Huang L, Feng S, Wang H. Decreased bone mineral density in female patients with systemic lupus erythematosus after long-term administration of Tripterygium Wilfordii Hook F. Clin Med J (Engl). 2000 Feb;113(2):159-61.

Interventional News. Transradial access for uterine artery embolization could be “a game changer.” Available at: http://www.cxvascular.com/in-latest-news/interventional-news---latest-news/transradial-access-for-uterine-artery-embolization-could-be-a-game-changer. 3/21/14. Accessed 7/3/14.

Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, . . . Bulun SE. High aromatase expression in uterine leiomyoma tissues of African-American women. The Journal of clinical endocrinology and metabolism. May 2009;94(5):1752-1756.

Ishikawa T, Glidewell-Kenney C, Jameson JL. Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5 alpha-reductase inhibitor. The Journal of steroid biochemistry and molecular biology. Feb 2006;98(2-3):133-138.

Islam MS. Uterine Leiomyoma: Available Medical Treatments and New Possible Therapeutic Options. The Journal of Clinical Endocrinology & Metabolism. 2013;98(3):921-934.

JCLHN. John C. Lincoln Health Network. Uterine Fibroid Symptoms. Available at: http://www.jcl.com/medical-services/uterine-fibroid-treatment/uterine-fibroid-symptoms. Copyright 2014. Accessed 12/29/2014.

Jebunnaher S, Begum SA. Parasitic leiomyoma: a case report. Mymensingh medical journal : MMJ. Jan 2013;22(1):173-175.

Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. International journal of women's health. 2014;6:95-114.

Khan N, Mukhtar H. Cancer and metastasis: prevention and treatment by green tea. Cancer metastasis reviews. Sep 2010;29(3):435-445.

Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA : the journal of the American Medical Association. Mar 5 2014;311(9):905-906.

Kiani F, et al. Effects of vitamin B6 on premenstrual syndrome: A systematic review and meta-Analysis. Journal of Chemical and Pharmaceutical Sciences. 2016;9(3): 1346-1353.

Kim A, Bridgeman MB. Ulipristal Acetate (ella): A Selective Progesterone Receptor Modulator For Emergency Contraception. P & T : a peer-reviewed journal for formulary management. Jun 2011;36(6):325-331.

Knoche AJ, Michaud LB, Buzdar AU. Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience. The breast journal. May 1999;5(3):176-181.

Kong S, Hou J, Xia M, Yang Y, Xu A, Tang Q. Association of Hyperglycemia, Hyperlipemia with the Risk of Uterine Leiomyomata: A Case-Control Study. Cancer Cell Research 2 (2014):37-41.

Kumsar S, Dirim A, Toksoz S, Saglam HS, Adsan O. Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR -P). Central European journal of urology. 2011;64(3):156-158.

Kuppermann M, Varner RE, Summitt RL, Jr., Learman LA, Ireland C, Vittinghoff E, . . . Washington AE. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA : the journal of the American Medical Association. Mar 24 2004;291(12):1447-1455.

Larson CA. Evidence-based medicine: an analysis of prophylactic bilateral oophorectomy at time of hysterectomy for benign conditions. Curr Oncol. Jan 2011;18(1):13-15.

Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. The Cochrane database of systematic reviews. 2007(4):CD000400.

Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. The Cochrane database of systematic reviews. 2001(2):CD000547.

Lev-Toaff AS, Coleman BG, Arger PH, Mintz MC, Arenson RL, Toaff ME. Leiomyomas in pregnancy: sonographic study. Radiology. 1987;164(2):375-380.

Li B, Takeda T, Tsuiji K, Kondo A, Kitamura M, Wong TF, Yaegashi N. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. Jan 2013;29(1):87-90.

Li R, Wang Y, Liu Y, Chen Q, Fu W, Wang H, . . . Zhang X. Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells. PloS one. 2013;8(3):e58848.

Ligon AH, Morton CC. Leiomyomata: heritability and cytogenetic studies. Human reproduction update. Jan-Feb 2001;7(1):8-14.

Liu JP, Yang H, Xia Y, Cardini F. Herbal preparations for uterine fibroids. The Cochrane database of systematic reviews. 2013;4:CD005292.

Livshits A, Seidman DS. Role of Non-Steroidal Anti-Inflammatory Drugs in Gynecology. Pharmaceuticals. 2010;3:2082-2089.

Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future oncology (London, England). Mar 2010;6(3):457-470.

Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian journal of endocrinology and metabolism. Oct 2011;15(4):261-267.

Malik M, Mendoza M, Payson M, Catherino WH. Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertility and sterility. May 2009;91(5 Suppl):2177-2184.

Mara M, Fucikova Z, Maskova J, Kuzel D, Haakova L. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. European journal of obstetrics, gynecology, and reproductive biology. Jun 1 2006;126(2):226-233.

Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovascular and interventional radiology. Jan-Feb 2008;31(1):73-85.

Mayo Clinic. Endometrial Ablation. Available at: http://www.mayoclinic.org/tests-procedures/endometrial-ablation/basics/definition/prc-20014190. Last updated 10/11/2012. Accessed 6/30/14.

Mayo Clinic. Iron Deficiency Anemia. Available at: http://www.mayoclinic.org/diseases-conditions/iron-deficiency-anemia/basics/definition/con-20019327. Last updated 1/2/2014b. Accessed 7/7/14.

Mayo Clinic. Myomectomy. Available at: http://www.mayoclinic.org/tests-procedures/myomectomy/basics/definition/prc-20012919. Last updated 6/4/13. Accessed 6/29/14.

Mayo Clinic. Oophorectomy. Available at: http://www.mayoclinic.org/tests-procedures/oophorectomy/basics/definition/prc-20012991. Last updated 4/24/14c. Accessed 8/8/14.

Mayo Clinic. Uterine Fibroids. Available at: http://www.mayoclinic.org/diseases-conditions/uterine-fibroids/basics/definition/con-20037901 Updated 4/9/2014a. Accessed 6/3/2014.

McCarthy AM, Menke A, Ouyang P, Visvanathan K. Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older. Cancer prevention research (Philadelphia, Pa.). Jun 2012;5(6):847-854.

Milad MP, Milad EA. Laparoscopic morcellator-related complications. Journal of minimally invasive gynecology. May-Jun 2014;21(3):486-491.

Miriello D,et al. Uterine fibroids treatment: do we have new valid alternative? Experiencing the combination of vitamin D plus epigallocatechin gallate in childbearing age affected women. Eur Rev Med Pharmacol Sci. 2021;25(7): 2843-2851.

Mitwally MF, Fischer RJ. ePocrates Online. Uterine Fibroids. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=567&ActiveSectionId=11. 2013. Accessed 10/11/2013.

Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, . . . Fini ME. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. The Journal of biological chemistry. Apr 7 2000;275(14):10405-10412.

Nagata C, Takatsuka N, Kawakami N, Shimizu H. Soy product intake and premenopausal hysterectomy in a follow-up study of Japanese women. European journal of clinical nutrition. Sep 2001;55(9):773-777.

Nappi L, Mele G, Angioni S, Cicinelli E, Greco P. Uterine leiomyosarcoma: report of three cases and review of the literature. European journal of gynaecological oncology. 2014;35(3):328-331.

NCCAM. National Center for Complementary and Alternative Medicine. Health Info page. Thunder God Vine. Available at: http://nccam.nih.gov/health/tgvine. Last updated 4/2012. Accessed 12/17/2014.

Nevarez Bernal RA, Chaya Hajj M, Velazquez Magana M, Vilchis Nava P, Buen-Abad EI. [A technique for total laparoscopic hysterectomy with vaginal morcellation on large uteri in order to maintain minimal invasion]. Ginecologia y obstetricia de Mexico. Dec 2012;80(12):769-771.

Orozco LJ, Tristan M, Vreugdenhil MM, Salazar A. Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women. The Cochrane database of systematic reviews. 2014;7:Cd005638.

Ozercan IH, Sahin N, Akdemir F, Onderci M, Seren S, Sahin K, Kucuk O. Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. Nutrition research (New York, N.Y.). Feb 2008;28(2):92-97.

Paffoni A, Somigliana E, Vigano P, Benaglia L, Cardellicchio L, Pagliardini L, . . . Fedele L. Vitamin D status in women with uterine leiomyomas. The Journal of clinical endocrinology and metabolism. Aug 2013;98(8):E1374-1378.

Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecologic oncology. Aug 2011;122(2):255-259.

Parker WH. Bilateral Oophorectomy versus Ovarian Conservation: Effects on Long-term Women's Health. Journal of minimally invasive gynecology. 3/2010;17(2):161-166.

Parker WH. Ovarian conservation versus bilateral oophorectomy at the time of hysterectomy for benign disease. Menopause (New York, N.Y.). Feb 2014;21(2):192-194.

Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, . . . Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstetrics and gynecology. May 2009;113(5):1027-1037.

Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, . . . Manson JE. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstetrics and gynecology. Apr 2013;121(4):709-716.

Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, . . . Schmidt EH. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertility and sterility. Jan 2010;93(1):192-198.

Phupong V, Darojn D, Ultchaswadi P. Parasitic leiomyoma: a case report of an unusual tumor and literature review. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Oct 2003;86(10):986-990.

Porcaro G, et al. Vitamin D plus epigallocatechin gallate: a novel promising approach for uterine myomas. Eur Rev Med Pharmacol Sci. 2020;24(6): 3344-3351.

Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertility and sterility. Apr 2009;91(4):1215-1223.

Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstetrics and gynecology. Jan 2005;105(1):67-76.

Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertility and sterility. Jan 2010;93(1):199-209.

Radin RG, Palmer JR, Rosenberg L, Kumanyika SK, Wise LA. Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. The American journal of clinical nutrition. May 2010;91(5):1281-1288.

Reich H, Maher PJ, Wood C. Laparoscopic hysterectomy. Bailliere's clinical obstetrics and gynaecology. Dec 1994;8(4):799-815.

Resnick NJ, Kim E, Patel RS, Lookstein RA, Nowakowski FS, Fischman AM. Uterine artery embolization using a transradial approach: initial experience and technique. Journal of vascular and interventional radiology : JVIR. Mar 2014;25(3):443-447.

Reuters. Gynesonics Receives CE Mark on Next Generation VizAblate® System for the Treatment of Symptomatic Uterine Fibroids. Available at: http://www.reuters.com/article/2014/06/12/ca-gynesonics-idUSnBw125383a+100+BSW20140612. 6/12/14a. Accessed 8/11/14.

Reuters. U.S. insurer to stop coverage of gynecological procedure. Available at: http://www.reuters.com/article/2014/08/02/highmark-procedure-idUSL2N0Q80IY20140802 Published 8/2/2014b. Accessed 8/18/2014.

Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Jr., Roger VL, Melton LJ, 3rd, Rocca WA. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause (New York, N.Y.). Jan-Feb 2009;16(1):15-23.

Roberts A. Magnetic resonance-guided focused ultrasound for uterine fibroids. Seminars in interventional radiology. Dec 2008;25(4):394-405.

Rocca WA, Shuster LT, Grossardt BR, Maraganore DM, Gostout BS, Geda YE, Melton LJ, 3rd. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Women's health (London, England). Jan 2009;5(1):39-48.

Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. International journal of women's health. 2013;5:477-486.

Rossetti A, Sizzi O, Soranna L, Cucinelli F, Mancuso S, Lanzone A. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Human reproduction (Oxford, England). Apr 2001;16(4):770-774.

Sabry M, Al-Hendy A. Innovative oral treatments of uterine leiomyoma. Obstetrics and gynecology international. 2012;2012:943635.

Sabry M, Halder SK, Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. International journal of women's health. 2013;5:93-100.

Sadlonova J, Kostal M, Smahelova A, Hendl J, Starkova J, Nachtigal P. Selected metabolic parameters and the risk for uterine fibroids. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. Jul 2008;102(1):50-54.

Salama SS, Kılıç GS. Uterine fibroids and current clinical challenges. Journal of the Turkish German Gynecological Association. 2013;14(1):40-45.

Sam S. Obesity and Polycystic Ovary Syndrome. Obesity management. Apr 2007;3(2):69-73.

Sanford M, Plosker GL. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs. 2008;68(9):1319-1340.

Serur E, Lakhi N. Laparoscopic hysterectomy with manual morcellation of the uterus: an original technique that permits the safe and quick removal of a large uterus. American journal of obstetrics and gynecology. Jun 2011;204(6):566.e561-562.

Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertility and sterility. Jan 2011;95(1):247-253.

Shoupe D, Parker WH, Broder MS, et al. Elective oophorectomy for benign gynecological disorders. Menopause. 2007;14(3 Pt 2):580-5.

Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause international. 2008;14(3):111-116.

Silva-Filho AL, Werneck RA, de Magalhaes RS, Belo AV, Triginelli SA. Abdominal vs vaginal hysterectomy: a comparative study of the postoperative quality of life and satisfaction. Archives of gynecology and obstetrics. Apr 2006;274(1):21-24.

Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod. May 2007;22(5):1450-1456.

Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. The Cochrane database of systematic reviews. 2013;10:Cd009505.

Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, . . . Gedroyc WM. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertility and sterility. Jan 2006;85(1):22-29.

Stine JE, Clarke-Pearson DL, Gehrig PA. Uterine morcellation at the time of hysterectomy: techniques, risks, and recommendations. Obstetrical & gynecological survey. Jul 2014;69(7):415-425.

Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women. American family physician. Jan 1 2012;85(1):35-43.

Takeda A, Mori M, Sakai K, Mitsui T, Nakamura H. Parasitic peritoneal leiomyomatosis diagnosed 6 years after laparoscopic myomectomy with electric tissue morcellation: report of a case and review of the literature. Journal of minimally invasive gynecology. Nov-Dec 2007;14(6):770-775.

Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, . . . Kimura T. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecologic and obstetric investigation. 2008;66(1):14-17.

Tinelli A, Hurst BS, Hudelist G, Tsin DA, Stark M, Mettler L, . . . Malvasi A. Laparoscopic myomectomy focusing on the myoma pseudocapsule: technical and outcome reports. Human reproduction (Oxford, England). Feb 2012;27(2):427-435.

Tristan M, Orozco LJ, Steed A, Ramirez-Morera A, Stone P. Mifepristone for uterine fibroids. The Cochrane database of systematic reviews. 2012;8:Cd007687.

Trivedi P, Abreo M. Predisposing factors for fibroids and outcome of laparoscopic myomectomy in infertility. Journal of gynecological endoscopy and surgery. Jan 2009;1(1):47-56.

Tsuiji K, Takeda T, Li B, Wakabayashi A, Kondo A, Kimura T, Yaegashi N. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. Jul 2011;27(7):512-517.

UMMC. University of Maryland Medical Center. Uterine fibroids. Available at: http://umm.edu/health/medical/ency/articles/uterine-fibroids. Last updated 5/20/2014. Accessed 6/3/2014.

Wallwiener M, Koninckx PR, Hackethal A, Brolmann H, Lundorff P, Mara M, . . . De Wilde RL. A European survey on awareness of post-surgical adhesions among gynaecological surgeons. Gynecological surgery. 2014;11:105-112.

Waltman H. The VizAblate System: Radiofrequency Ablation for the Treatment of Symptomatic Uterine Fibroids. Available at: http://www.obgyn.net/fibroids/vizablate-system-radiofrequency-ablation-treatment-symptomatic-uterine-fibroids. Last updated 11/1/11. Accessed 7/3/14.

Wang BX, Yuan ZZ. [A tablet of Tripterygium wilfordii in treating lupus erythematosus]. Zhong Xi Yi Jie He Za Zhi. 1989 Jul;9(7):407-8, 389.

Watson Pharma Inc. Ella (ulipristal acetate): Highlights of Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf. Last updated 8/2010. Accessed 8/10/14.

Wen Q. Therapeutic observation on effect of Tripterygium Wilfordii Hook and mifepristone in treatment of uterine leiomyoma. Clinical Medicine of China. 2005;21(3):277-9.

Whitaker LH, Williams AR, Critchley HO. Selective progesterone receptor modulators. Current opinion in obstetrics & gynecology. Aug 2014;26(4):237-242.

Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, Rosenberg L. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Human reproduction (Oxford, England). Aug 2004;19(8):1746-1754.

Wise LA, Palmer JR, Spiegelman D, Harlow BL, Stewart EA, Adams-Campbell LL, Rosenberg L. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology (Cambridge, Mass.). May 2005;16(3):346-354.

Wise LA, Palmer JR, Stewart EA, Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertility and sterility. May 2007;87(5):1108-1115.

Wise LA, Radin RG, Palmer JR, Kumanyika SK, Boggs DA, Rosenberg L. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. The American journal of clinical nutrition. Dec 2011;94(6):1620-1631.

Wise LA, Radin RG, Palmer JR, Kumanyika SK, Rosenberg L. A prospective study of dairy intake and risk of uterine leiomyomata. American journal of epidemiology. Jan 15 2010;171(2):221-232.

Xi S, Liske E, Wang S, et al. Effect of Isopropanolic Cimicifuga racemosa Extract on Uterine Fibroids in Comparison with Tibolone among Patients of a Recent Randomized, Double Blind, Parallel-Controlled Study in Chinese Women with Menopausal Symptoms. Evid Based Complement Altern Med. 2014;2014:717686. [Epub 2014 Mar 2].

Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life sciences. May 16 2007;80(23):2161-2169.

Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D, Seidman DS. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertility and sterility. Feb 2014;101(2):496-500.

Yoshida A, Nii S, Matsushita H, Morii Y, Watanabe K, Wakatsuki A. Parasitic myoma in women after laparoscopic myomectomy: A late sequela of morcellation? Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. Aug 11 2014:1-2.

Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertility and sterility. Oct 2010;94(5):1887-1893.

Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC women's health. 2012;12:6.